A Phase 3b, Open-label, Multicenter, Continued Access Study for Participants Transitioning From ViiV Healthcare Sponsored or ViiV Healthcare Collaborative Parent Studies for HIV Treatment
Latest Information Update: 11 Feb 2026
At a glance
- Drugs Dolutegravir/lamivudine (Primary) ; Fostemsavir (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Registrational
- Acronyms PATH
- Sponsors ViiV Healthcare
Most Recent Events
- 11 Feb 2026 New trial record